Nasdaq

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
AOL

Woman Says She Could 'Suffocate or Die' If She Lies Flat, Even During Sleep, After Vaping Habit

Loyda Cordero Faliero, 39, switched from smoking to vaping, but said the new habit caused her to develop air pockets in her lung walls, a condition called bullous emphysema, according to the Cleveland ...
The American Journal of Managed Care

Skin-Related Quality of Life Worsens With Autoimmune Bullous Disease Flare-Ups

Clinical measurements of skin-related quality of life (SRQL) may aid in detecting critical disease severity information. Skin-related quality of life (SRQL) may be associated with flare-ups in ...
Oregonian

Dear Doctor: Patient with rare autoimmune disease - bullous pemphigoid - seeks a new treatment

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...
Nasdaq

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...